Table 4.
General characteristics of tumors by sentinel lymph node tumor (categorical data).
| Features of tumors | Sentinel lymph node involvement | P | ||
|---|---|---|---|---|
| Absent (n, %) | Present (n, %) | |||
| Tumor size | ≤2 cm | 180, 69.2% | 80, 30.8% | <.001 * |
| >2 cm | 71, 38.4% | 114, 61.6% | ||
| Tumor histology | IDC | 188, 54.3% | 158, 45.7% | <.001 * |
| ILC | 5, 27.8% | 13, 72.2% | ||
| Special types* | 36, 83.7% | 7, 16.3% | ||
| Other† | 22, 57.9% | 16, 42.1% | ||
| ER (%) | Negative | 53, 57.6% | 39, 42.4% | .794 |
| Positive | 198, 56.1% | 155, 43.9% | ||
| PR (%) | Negative | 51, 56.7% | 39, 43.3% | .955 |
| Positive | 200, 56.3% | 155, 43.7% | ||
| Ki-67 score (≥7.5%) | Negative | 60, 70.6% | 25, 29.4% | <.001 * |
| Positive | 56, 44.8% | 69, 55.2% | ||
| Ki-67 score (≥14%) | Negative | 74, 61.7% | 46, 38.3% | .031 * |
| Positive | 42, 46.7% | 48, 53.3% | ||
| HER2 | Negative | 219, 61.2% | 139, 38.8% | <.001 * |
| Positive | 32, 36.8% | 55, 63.2% | ||
| Triple negativity | No | 222, 55.4% | 179, 44.6% | .180 |
| Yes | 29, 65.9% | 15, 34.1% | ||
| Accompanying DCIS or LCIS | Absent | 96, 60.8% | 62, 39.2% | .169 |
| Present | 155, 54.0% | 132, 46.0% | ||
| LVI | Absent | 220, 75.6% | 71, 24.4% | <.001 * |
| Present | 31, 20.1% | 123, 79.9% | ||
| Histological grade | I | 88, 73.3% | 32, 26.7% | <.001 * |
| II | 109, 50.7% | 106, 49.3% | ||
| III | 54, 49.1% | 56, 50.9% | ||
DCIS = Ductal carcinoma in situ, ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, LVI = lymphovascular invasion, LCIS = lobular carcinoma in situ, PR = progesterone receptor.
*
Special types: papillary carcinoma, mucinous carcinoma, tubular carcinoma;
†
Other types: medullary carcinoma, cribriform carcinoma, adenoid cystic carcinoma, micropapillary carcinoma, apocrine carcinoma, and microinvasive carcinoma ≥1% were considered positive.
* P < .05.